Skip to content
APAXEN

APAXEN

BREAKTHROUGH THERAPIES FOR CHRONIC INFLAMMATORY DISEASES WITH A PRIMARY FOCUS IN PULMONARY ARTERIAL HYPERTENSION (PAH)

  • ABOUT-US
  • NEWS
  • TEAM
  • DISEASES
  • SCIENCE
    • PIPELINE
    • R&D STRATEGY
    • MIF as a therapeutic target in PAH
    • MFC-1040
  • PARTNERSHIP
  • INVESTORS

Category: Press releases

Apaxen raises €3.3 million in Series A Financing to Develop Breakthrough Anti-inflammatory Therapeutics for Pulmonary Arterial Hypertension (PAH)

11/09/201911/11/2020 by devin Press releasesLeave a Comment on Apaxen raises €3.3 million in Series A Financing to Develop Breakthrough Anti-inflammatory Therapeutics for Pulmonary Arterial Hypertension (PAH)
Download the press release
Télécharger le communiqué

Apaxen

Rue Auguste Piccard,48
6041 Gosselies Belgium
bart.wuurman@apaxen.com